BioSpace News Archive

Dr. Kirk will oversee the ACGME’s specialty and subspecialty Review and Recognition Committee activities relating to the review of residency and fellowship programs.

The US National Cancer Institute has awarded Bound Therapeutics LLC a Small Business Technology Transfer grant starting 15 June for $300,000 to develop “microRNA-21 Blockade of Triple Negative Breast Cancer”.

Signify Health has announced the launch of Signify Community, the first and only social determinants of health solution that ties social interventions to quality, satisfaction, and financial outcomes—including 30% reductions in readmissions and 46% reductions in post-acute care spend for high-utilizer safety net populations.

Phreesia announced it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its common stock.

Study will evaluate improved clinical outcomes in patients using the Prospera™ dd-cfDNA test [24-June-2019] SAN CARLOS, Calif. , June 24, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a nationwide registry study for kidney transplant recipients called ProActive. This is one of the largest known prospect

Avellino Labs, a global biotechnology and genetic science innovator, announced today the company’s founder, chairman and president, Gene Lee, is a recipient of a 2019 Ellis Island Medal of Hono

MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed a non-exclusive, performance-based distribution agreement with Group Vida, to distribute MedX’s DermSecureTM skin cancer assessment technology platform in the USA, Canada and Israel.

DPC Healthcare launched Texas’ first mobile, direct primary care clinic in June 2019 to address one of the biggest barriers to healthcare access: time.

- FDA removed the partial clinical hold based upon agreement on revisions to the CANOVA study protocol, including new risk mitigation measures, protocol-specified guidelines and updated futility criteria

Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced delivery of the 100,000th patient dose of SIR-Spheres® Y-90 resin microspheres, a treatment for patients with liver cance